X
GO

Dr. Michele Carbone's Scientific Publications

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

published in Translational Lung Cancer Research, June 16, 2017

A review of the most promising biomarkers for early detection of malignant mesothelioma.
0 Comments
Mesothelioma: Recent Highlights

Mesothelioma: Recent Highlights

Annals of Translational Medicine 2017: Review Article

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. 
0 Comments
Malignant Mesothelioma: Time to Translate?

Malignant Mesothelioma: Time to Translate?

Opinion: Lessons from the Clinic

Malignant Mesothelioma is a rare and poorly understood cancer with limited therapeutic approaches.

0 Comments
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

Differentiating between pleural malignant mesothelioma (MM) and lung cancer is often challenging. Immunohistochemical (IHC) stains used to distinguish these malignancies include markers  that are most often positive in malignant mesothelioma and less frequently positive in carcinomas, and vice versa. However, in 10 to 20% of the cases, the immunohistochemical staining results can be confusing and inconclusive,  and novel markers are sought to increase the diagnostic accuracy.

We stained 45 non-small cell lung cancers (32 adenocarcinomas and 13 squamous cell carcinomas) with a monoclonal antibody for BRCA1-associated protein 1 (BAP1) and also with an IHC panel we routinely use to help differentiate MM from carcinomas, which include calretinin, Wilms Tumor 1, cytokeratin 5, podoplantin D2-40, pankeratin CAM5.2, thyroid transcription factor 1, Napsin-A,  and p63.  Nuclear BAP1 expression was also analyzed in 35 MM biopsies. All 45 non-small cell lung cancer biopsies stained positive for nuclear BAP1, whereas 22/35 (63%)  MM biopsies lacked nuclear BAP1 staining, consistent with previous data. Lack of BAP1 nuclear staining was associated with MM. Focal BAP1 staining was observed in a subset of samples, suggesting polyclonality. Diagnostic accuracy of other classical IHC markers was in agreement with previous studies. Our study indicated that absence of nuclear BAP1 staining helps differentiate MM from lung carcinomas. We suggest that BAP1 staining should be added to the IHC panel that is currently used to distinguish these malignancies.  

 Authors: Michele Carbone, David Shimizu, Andrea Napolitano, Mika Tanji,  Harvey I. Pass, Haining Yang, Sandra Pastorino

0 Comments
RSS